Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile

西妥昔单抗 尼妥珠单抗 化学 表皮生长因子受体 抗体 癌症研究 体外 单克隆抗体 细胞 细胞生长 受体 药理学 生物 分子生物学 免疫学 医学 生物化学
作者
Greta Garrido,Ilia A. Tikhomirov,Ailem Rabasa,Eric C.C. Yang,Elías Gracia,Normando Iznaga,Luis Enrique Fernandez,Tania Crombet,Robert S. Kerbel,Rolando Pérez
出处
期刊:Cancer Biology & Therapy [Taylor & Francis]
卷期号:11 (4): 373-382 被引量:165
标识
DOI:10.4161/cbt.11.4.14097
摘要

Nimotuzumab is an EGFR-targeting antibody that has demonstrated encouraging clinical results in the absence of severe side-effects observed with other approved anti-EGFR antibodies. We investigated whether different clinical behavior of nimotuzumab is related to its bivalent/monovalent binding profile. Binding properties of nimotuzumab and cetuximab, the most development of anti-EGFR antibodies, were studied in vitro using chip surfaces and cells with varying EGFR expression levels. Experimental observations demonstrated that in contrast to cetuximab, the intrinsic properties of nimotuzumab required bivalent binding for stable attachment to the cellular surface, leading to nimotuzumab selectively binding to cells that express moderate to high EGFR expression levels. At these conditions, both antibodies bound bivalently, and accumulated to similar degrees. When EGFR density is low, nimotuzumab monovalent interaction was transient, whereas cetuximab continued to interact strongly with the receptors. We compared the in vitro anti-tumor efficacy of nimotuzumab and cetuximab. Cetuximab decreased the cell viability and induced apoptosis for all the tested cell lines, effects which did not depend on EGFR expression level. In contrast, nimotuzumab also provoked significant anti-cellular effects, but its anti-tumor capacity decreased together with EGFR expression level. Cetuximab Fab fragment was able to impact tumor cell survival, whereas nimotuzumab fragment totally lost this effect. Tumor-xenograft experiments using cells with a high EGFR expression revealed similar tumor growth inhibiting effects for both antibodies. This study suggests an explanation for nimotuzumab clinical profile, whereby anti-tumor activity is obtained in absence of severe toxicities due to its properties of bivalent binding to EGFR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顾矜的应助被大力的源智采纳,获得10
刚刚
刚刚
1秒前
ypp发布了新的文献求助10
2秒前
3秒前
ll发布了新的文献求助10
4秒前
4秒前
5秒前
栗子对应助文件撤销了驳回
5秒前
香蕉觅云的应助被李瑞程采纳,获得10
5秒前
5秒前
SciGPT的应助被有缘采纳,获得10
5秒前
爽飞边芷了完成签到,获得积分10
6秒前
香蕉寒珊的应助被王大橙子采纳,获得10
6秒前
Valerie发布了新的文献求助10
6秒前
bkagyin的应助被lmy采纳,获得10
6秒前
CodeCraft的应助被hml123采纳,获得10
7秒前
麦粑块发布了新的文献求助10
7秒前
7秒前
王萍有发布了新的文献求助10
7秒前
8秒前
8秒前
细腻荔枝完成签到 ,获得积分10
9秒前
9秒前
酷波er的应助被Lily采纳,获得10
9秒前
Joany完成签到,获得积分10
10秒前
10秒前
10秒前
11秒前
欧科狗完成签到,获得积分10
11秒前
11秒前
xiaobao完成签到,获得积分20
11秒前
核桃的应助被ss采纳,获得30
12秒前
12秒前
Orange的应助被ss采纳,获得10
12秒前
困困的老猫完成签到,获得积分10
12秒前
13秒前
13秒前
大力的源智完成签到,获得积分10
13秒前
慕青的应助被现实的翅膀采纳,获得20
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239